OpenAI Explores Marketplace: Empowering Developers to Monetize AI Models on Microsoft’s ChatGPT

Microsoft Corp (NASDAQ: MSFT) backed ChatGPT parent OpenAI eyes a marketplace to allow developers to sell their AI models built on top of its 

Microsoft Corp (NASDAQ:MSFT) backed ChatGPT parent OpenAI eyes a marketplace to allow developers to sell their AI models built on top of its own AI technology.

The makers of such AI software’s advanced large language models (LLMs) could offer them to other businesses through OpenAI’s proposed marketplace, Reuters cites media sources.

OpenAI CEO Sam Altman disclosed the potential plans during a meeting with developers in London in May.

Also Read: ChatGPT’s Parent Might Not Get An IPO Anytime Soon: ‘I Don’t Want To Be Sued,’ CEO Sam Altman Says

Such a marketplace could compete with app stores run by some of the company’s customers and technology partners – including Salesforce, Inc (NYSE:CRM) and Microsoft and help OpenAI’s technology reach a broader customer base.

Reportedly, two of OpenAI’s customers, Aquant, which makes software manufacturers use to direct customers through device maintenance and repairs, and education app maker Khan Academy, might be interested in offering their ChatGPT-powered AI models on OpenAI’s marketplace.

Price Action: MSFT shares traded lower by 1.05% at $338.73 on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

Kyivstar Provides Update On Cyber-Attack Recovery; Reports Partial Restoration Of Connectivity On Its Fixed Network; Technical Teams Are Working On Restoring All Services, With Intention Of And The Best Effort Towards Achieving Recovery Starting Dec 13

VEON Ltd. (NASDAQ:VEON, Euronext Amsterdam: VEON)))), a global digital operator that provides converged connectivity and online services, notes the following updates from its Ukrainian subsidiary Kyivstar regarding the

VEON

Read More

Seagen Inc. Announces New Data For ADCETRIS With Immunotherapy Combination In Hodgkin Lymphoma To Be Featured At 2023 ASH Annual Meeting, And Seagen To Unveil Novel CD30-Directed Antibody-Drug Conjugate

– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session –– First preclinical data for investigational antibody-drug

SGEN